Of the BRAF-targeted agents, Sorafenib has progressed to approval by the United States Food and Drug Administration for therapy of renal cell carcinoma and is under evaluation for melanoma, thyroid cancer and other malignancies. The gene discussed is BRAF; the disease is renal cell carcinoma.